CIBINQO, known generically as abrocitinib, is a prescription medication designed for the treatment of moderate to severe atopic dermatitis (eczema) in individuals who are candidates for systemic therapy. It belongs to a class of drugs known as Janus kinase (JAK) inhibitors, which work by interfering with the signaling pathway that leads to inflammation. By targeting specific enzymes in this pathway, CIBINQO effectively reduces the symptoms of atopic dermatitis, such as itching and redness, providing relief for individuals suffering from this chronic skin condition. It is available in tablet form and is taken orally, making it a convenient option for patients seeking an alternative to topical treatments or those who require systemic therapy for their condition.